News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aduro Biotech Announces Initation Of A Clinical Trial Of Its Novel Immunotherapy In Patients With Brain Cancer At Providence Cancer Center



5/5/2014 8:50:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the first patients have been enrolled in a Phase 1 clinical trial to evaluate its novel immunotherapy ADU-623 in patients with high-grade glioma, a form of brain cancer. The trial is being conducted by leading investigators at the Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Oregon. The project has been funded by grants from the Kuni Foundation and Providence Portland Medical Foundation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES